China National Biotec Is Said to Plan $1.5 Billion Hong Kong IPO
The unit of Sinopharm Group Co. (1099) may file an application to Hong Kong’s stock exchange by the end of March and start the offering as early as in the second quarter, said the people, who asked not to be identified because the information is private. Sinopharm is China’s biggest pharmaceutical distributor by market value.
China International Capital Corp., Morgan Stanley and UBS AG will manage the offering, the people said. An external spokeswoman for National Biotec declined to comment on the plan.
National Biotec, based in Beijing, is the fourth-biggest vaccine maker in the world, according to its website. It has about 8.6 billion yuan ($1.4 billion) of assets and annual sales of more than 5 billion yuan, the website shows.
To contact the reporter on this story: Fox Hu in Hong Kong at email@example.com
To contact the editor responsible for this story: Philip Lagerkranser at firstname.lastname@example.org
Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.